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processing has been recently addressed. We studied the
role of the infralimbic cortex (IL) and group I metabotropic
glutamate receptors (mGluRs) in descending modulation
of nociception in control and monoarthritic (ARTH) condi-
tions. Nociception was assessed using heat-induced paw
withdrawal while drugs were microinjected in the IL of rats.
Local anesthesia of the IL or the adjacent prelimbic cortex
(PL) facilitated nociception, indicating that IL and PL are
tonically promoting spinal antinociception. Phasic activa-
tion with glutamate (GLU) revealed opposing roles of the
PL and IL; GLU in the PL had a fast antinociceptive action,
while in the IL it had a slow onset pronociceptive action.
IL administration of a local anesthetic or GLU produced
identical results in ARTH and control animals. An mGluR5
agonist in the IL induced a pronociceptive eﬀect in both
groups, while mGluR5 antagonists had no eﬀect in controls
but induced antinociception in ARTH rats. Activation of the
IL mGluR1 (through co-administration of mGluR1/5 agonist
and mGluR5 antagonist) did not alter nociception in
controls but induced antinociception in ARTH animals. IL
administration of an mGluR1 antagonist failed to alter noci-
ception in either experimental group. Finally, mGluR5 but
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108of GLU in both groups. The results indicate that IL con-
tributes to descending modulation of nociception. mGluR5
in the IL enhance nociception in healthy control and mono-
arthritic animals, an eﬀect that is tonic in ARTH. Moreover,
activation of IL mGluR1s attenuates nociception following
the development of monoarthritis.  2015 IBRO. Published
by Elsevier Ltd. All rights reserved.
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In the last decade, there has been increasing evidence of
the involvement of the prefrontal cortex (PFC) in the
processing of the aﬀective component of pain. It
has been shown in both humans and animal models
that, in chronic pain conditions, the PFC undergoes
morphological and functional changes. These changes
include decreased gray matter density in patients with
chronic back pain (Apkarian et al., 2004). Increased med-
ial PFC (mPFC) activation is correlated with the intensity
and duration of spontaneous pain in patients with chronic
pain (Baliki et al., 2006). Increases in the length, number
of branches and spine density of basal dendrites of mPFC
neurons as well as an increase in the NMDA/AMPA
receptors ratio have been described in a rat model of neu-
ropathic pain (Metz et al., 2009). Additionally, high-
frequency electrical stimulation of the dorsal component
of the mPFC, the anterior cingulate cortex (ACC), has
been shown to be pronociceptive, decreasing heat-
evoked paw withdrawal latencies (Zhang et al., 2005).
Less is known, however, of the pain modulatory role of
the anatomically and functionally distinct ventral mPFC
(Heidbreder and Groenewegen, 2003; Vertes, 2006) that
consists of the prelimbic (PL) and infralimbic (IL) cortices
in the rodent brain. Zhang et al. (2004) have evaluated the
electrophysiological responses of mPFC neurons (ACC,
PL and IL) to mechanical noxious stimulation of the rat’s
tail, and were able to distinguish two subsets of respond-
ing neurons (nociceptive speciﬁc and wide-dynamic
range-like neurons) that seem to encode nociceptive
stimulus intensity.
In the present work, we studied the contribution of the
IL to the modulation of nociception in the rat. We used
local cerebral microinjections to generally activate and
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descending modulation of nociceptive behavior of rats.
Furthermore, we used speciﬁc receptor agonists and
antagonists for group I glutamate metabotropic
receptors (mGluRs; includes receptors 1 and 5 –
mGluR1 and mGluR5), in order to assess their
involvement in IL-mediated descending modulation of
nociception. The role of these receptors upon
nociceptive modulation has been studied in several
supraspinal brain areas (Palazzo et al., 2001;
Neugebauer, 2002; Li and Neugebauer, 2004; Ren and
Dubner, 2010), including the PL in the mPFC, where the
blockade of mGluR1 can reverse the inhibition of neuronal
spontaneous ﬁring observed in sustained inﬂammatory
pain (Ji and Neugebauer, 2011). Lastly, we investigated
the impact of experimental monoarthritis upon IL-driven
descending modulation of nociception.
EXPERIMENTAL PROCEDURES
Animals, anesthetics and ethical issues
The experiments were performed in adult Wistar Han
male rats weighting 250–300 g (Charles River, France).
The experimental protocol was approved by the
Institutional Ethics Commission and followed the
European Community Council Directive 2010/63/EU
concerning the use of animals for scientiﬁc purposes. All
eﬀorts were made to minimize animal suﬀering and to
use only the number of animals necessary to produce
reliable scientiﬁc data.
During intracerebral cannula implantation, anesthesia
was induced through the intraperitoneal (i.p.)
administration of a mixture of ketamine (0.75 mg/kg, i.p.;
Imalgene, Merial Lyon, France) and medetomidine
(0.5 mg/kg, i.p.; Dorbene, Esteve Veterinaria, Le´on,
Spain). After the surgical procedures, anesthesia was
reverted with atipamezole hydrochloride (1 mg/kg, i.p.;
Antisedan, Orion Pharma, Orion Corporation, Espoo,
Finland) and the animals were monitored until they were
fully recovered. After the completion of the behavioral
tasks, animals received a lethal dose of pentobarbitone
and the brains were removed for histological
conﬁrmation of cannula placement (Fig. 1).
Procedures for intracerebral injections
For intracerebral drug administration, cannulae were
implanted as described by Pinto-Ribeiro et al. (2011).
Brieﬂy, rats were placed in a stereotaxic frame, a longitu-
dinal incision was made in the scalp, which was retracted
as well as the subcutaneous fascia, and a sterilized
stainless-steel guide cannula (26 gauge; Plastics One,
Roanoke, VA, USA) was implanted in the brain through
a hole drilled in the skull. The tip of the guide cannula
was positioned 1 mm above the right IL or PL (as a place-
ment control) using the following stereotaxic coordinates:
IL: 2.76 mm frontal to bregma; 0.6 mm lateral to midline;
depth 4.2 mm; and PL: 2.76 mm frontal to the bregma;
0.6 mm lateral to midline; depth 3.5 mm (Paxinos and
Watson, 2005). The guide cannula was ﬁxed to the skull
with screws and dental acrylic cement and the skin
sutured around it. A dummy cannula (Plastics One) wasinserted into the guide cannula to prevent contamination
and the animals were allowed to recover from the surgery
for at least one week.
Test drugs were administered through a 33-gauge
injection cannula (Plastics One) protruding 1 mm beyond
the tip of the guide cannula. The microinjection was
performed using a 5.0 lL Hamilton syringe connected to
the injection cannula by a polyethylene catheter (PE-10;
Plastics One). The injection volume was 0.5 lL and
therefore, the spread of the injected drugs within the
brain was expected to have a diameter of 1 mm (Myers,
1966). The eﬃcacy of the injection was monitored by
observing the movement of a small air bubble through the
tubing. The injection lasted at least 20 s and the injection
cannula was left in place for additional 30 s to minimize
the return of drug solution back to the injection cannula.Induction of monoarthritis
The induction of a model of monoarthritis (ARTH) was
performed 21 days before the beginning of the
experiments, as described in detail elsewhere (Pinto-
Ribeiro et al., 2013). Brieﬂy, 3% kaolin and 3%
carrageenan (Sigma–Aldrich, St. Louis, MO, USA) were
dissolved in distilled water and injected into the synovial
cavity of the right knee joint at a volume of 0.1 mL. This
model produces mechanical hyperalgesia, which begins
just in a few hours after surgery and extends up to 8 weeks
(Radhakrishnan et al., 2003). In each animal, ARTH devel-
opment was veriﬁed 1–2 h prior to each experiment. Only
those rats that audibly vocalized every time after ﬁve ﬂex-
ion–extension movements of the knee joint were consid-
ered to have monoarthritis, and they were included in the
ARTH group (Pinto-Ribeiro et al., 2011, 2013; Amorim
et al., 2014). Control animals (SHAM) were injected with
0.1 mL saline in the synovial cavity of the right knee joint.
SHAM animals did not vocalize to any of the ﬁve consecu-
tive ﬂexion–extension movements of the knee joint.
Additionally, we used the pressure application
measurement (PAM) to verify the development of primary
mechanical hyperalgesia in ARTH animals (Barton et al.,
2007). To perform the test, the animal is held securelywhile
the force transducer unit (ﬁtted to the experimenter’s
thumb) is placed on one side of the knee joint and the fore-
ﬁnger on the other. Increasing force (0–1500 g) is gradually
applied across the joint until a behavioral response is
observed (paw-withdrawal, vocalization, wriggling or
vocalization), with a cut-oﬀ of 5 s. The peak force (in grams
of force (gf)) applied immediately prior to the behavioral
response is registered as the limb withdrawal threshold
(LWT). LWT was measured twice in both the ipsilateral
and contralateral limbs at 1-min intervals. Themean LWTs
were calculated per animal. At the end of the session ani-
mals were returned to their home cage.Behavioral assessment of nociception – Hargreaves
model
Prior to performing the behavioral tests, rats were
habituated to the experimental conditions (i) by allowing
them to spend 1–2 h daily in the testing room during the
week preceding any testing, and (ii) by performing daily
Fig. 1. Anatomical conﬁrmation of drug injection sites in the prelimbic (PL) and infralimbic (IL) cortices. (A) Photomicrograph of an example of the
drug injection site in the IL of the rat brain (AP: +3.72 mm from bregma) superimposed with the appropriate legend of Paxinos and Watson (2005)
stereotaxic atlas. (B–F) Schematic representation of other injection sites in the PL and IL (B: +3.72 mm, C: +3.24 mm, D: +3.00 mm, E:
+2.76 mm; F: +2.52 mm). DP – dorsal peduncular cortex; IL – infralimbic cortex; PL – prelimbic cortex.
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unanesthetized animals, the latency of hindpaw
withdrawal following radiant heat stimulation (Hargreaves
test; Plantar Test Device Model 37370, Ugo Basile,
Comerio, Italy) was determined. In each behavioral
session, the withdrawal latency was assessed prior to
drug administration and at various intervals following the
intracerebral injections (Fig. 2). At each time point, the
measurements were repeated twice at an interval of
1 min (except for glutamate (GLU) due to its fast eﬀect)
and the mean of these values was used in further
calculations. The cut-oﬀ time for radiant-heat exposure
was set at 15 s in order to avoid any damage to the skin.
Drugs
GLU (Merck, Darmstadt, Germany), (RS)-2-chloro-5-
hydroxyglycine (CHPG; mGluR5 agonist), (S)-3,5-
dihydroxyphenylglycine (DHPG; mGluR1/5 agonist; Tocris,
Bristol, United Kingdom), and 3-((2-Methyl-1,3-thiazol-4-yl)
ethynyl)pyridine hydrochloride (MTEP; mGluR5 antagonist,
Tocris, Bristol, United Kingdom) solutions for intracerebral
drug injection were prepared with sterilized saline solution
0.9% (Unither, Amiens, France; pH 7,2). 6-Methyl-2-
(phenylethynyl)pyridine (MPEP; mGluR5 antagonist;
Tocris, Bristol, United Kingdom) was dissolved in 10%
dimethyl sulfoxide (DMSO). (S)-(+)-a-Amino-4-carboxy-2-
methylbenzeneacetic acid (LY367385; mGluR1 antagonist)
was dissolved in 2% sodium hydroxide solution (NaOH).
Lidocaine (2%; LIDO) was acquired as a solution
(B. Braun Medical, Barcarena, Portugal).
Previous studies showed that the 50 nmol dose of
GLU (Pinto-Ribeiro et al., 2011), DHPG, CHPG (Ansah
et al., 2009) and MPEP (Movsesyan et al., 2001) and
the 40 nmol dose of LY367385 (de Novellis et al., 2005)are eﬀective in activating/blocking mGluRs after intracere-
bral microinjection in the rat. Since there are studies
suggesting that MPEP has signiﬁcant non-speciﬁc
actions, including inhibition of NMDA receptors (Lea and
Faden, 2006) and positive allosteric modulation of
mGluR4 (Mathiesen et al., 2003), MTEP was also used
and their eﬀects compared. The MTEP dose (50 nmol)
used was the same as for MPEP to allow the comparison
of the two antagonists’ eﬃcacy. An observation window of
50 min was determined by evaluating alterations in noci-
ceptive behavior at ﬁxed time points (Fig. 2) until the drug
eﬀect was no longer observed. Control injections with the
respective vehicle (VEH) solutions were performed as
control values, in order to avoid any bias that might result
from injecting the solution itself.
Rotarod test
To exclude motor eﬀects of drug injection in the IL, motor
performance was evaluated on a Rotarod equipment
(3376-4R; TSE Systems, USA) using an accelerating
protocol. In this protocol, SHAM and ARTH animals
were placed on a rod that accelerated smoothly from 4
to 40 rotations per minute (rpm) over a period of 5 min.
The ﬁrst 3 days of protocol served as training. In each
day, rats underwent the accelerating protocol for a total
of 4 trials per day, with a rest of at least 20 min between
each trial. On the following days, the eﬀect of each drug
upon motor performance was tested on the same
accelerating protocol and the latency to fall was
recorded (Monville et al., 2006). Due to the small window
of drug action observed in the Hargreaves model, during
drug testing animals underwent only two trials of the
accelerating protocol, 10 and 30 min after drug adminis-
tration (Fig. 2).
Fig. 2. Schematic representation of the experimental design timeline. Rats were habituated to the laboratory and the experimenter for 5 days. After
habituation, animals belonging to the arthritic (ARTH) group received an intra-synovial injection of 3% kaolin/carrageenan while control (SHAM)
animals received an intra-synovial injection of saline solution. Two weeks after monoarthritis induction, animals were implanted with a guide cannula
in the infralimbic (IL) or in the prelimbic (PL) cortices. After recovery (one week), rats performed the pressure application measurement (PAM) and
were trained in the paw-withdrawal apparatus. Pharmacological tests were performed at the same time points for all the drugs. min – minutes; W1–5
– weeks 1 to 5.
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Three weeks after ARTH induction and at least one week
after guide cannula implantation, animals were trained in
the Hargreaves test. Four weeks after ARTH induction,
the tonic and phasic action of the IL and PL and the eﬀect
of the activation/inactivation of mGluR1 and/or mGluR5 in
the IL upon nociceptive behavior were determined in
unanesthetized animals through the assessment of
changes in paw withdrawal latency (PWL) after drug
injection. Withdrawal latencies were assessed 1, 10, 20,
30, 40 and 50 min following intracerebral injections
(Fig. 2). The interval between behavioral assessments of
diﬀerent drugs was of at least three days. The order for
testing each diﬀerent drug was randomized among
animals. Animals were injected with a maximum of ﬁve
diﬀerent drugs, in random order.
Statistics
Using the GraphPad Prism 5 software (GraphPad Software
Inc., La Jolla, CA, USA), a two-way analysis of variance
(ANOVA) followed by t-test with a Bonferroni correction for
multiple comparisons was used to compare behavioral
results among experimental groups. P< .05 was
considered to represent a signiﬁcant diﬀerence. Data are
presented as mean± standard error of the mean (SEM).
RESULTS
Healthy animals
GLU-induced activation of PL and IL has opposite
phasic eﬀects on nociceptive behavior in healthy rats. Inorder to study a possible phasic role of the PL and the IL
upon nociceptive behavior in healthy rats, we
microinjected GLU into these areas and evaluated
changes in the heat-evoked PWL of SHAM animals.
Overall, GLU administration in the PL had an
antinociceptive eﬀect in SHAM animals, as revealed by
an increase in the PWL (main eﬀect of GLU:
F1,120 = 4.99; P= 0.0273), and this eﬀect varied with
time (interaction drug eﬀect  time: F5,120 = 2.36,
P= 0.0415). Post hoc tests showed that GLU treatment
of the PL induced a short-lasting antinociceptive eﬀect
that was maximal 1 min after GLU injection and that
disappeared within 10 min (Fig. 3A). In contrast, GLU
administration in the IL resulted in a pronociceptive eﬀect
as revealed by the decrease of the PWL in SHAM
animals (main eﬀect of GLU: F1,40 = 15.73; P= 0.0003),
and this pronociceptive eﬀect varied with time (interaction
drug  time: F5,40 = 3.88, P= 0.0059). While the
antinociceptive eﬀect induced by GLU in the PL was of
rapid onset and short duration, post hoc tests indicated
that GLU in the IL induced a pronociceptive eﬀect that
was signiﬁcant from 10 to 30 min after GLU injection
(Fig. 3C).
Local anesthesia of both PL and IL reveals tonic
antinociceptive eﬀects in healthy rats. To evaluate a
possible tonic role of the PL and the IL in the
descending control of nociceptive behavior in healthy
rats, we microinjected LIDO, a local anesthetic, and
evaluated changes in heat-evoked PWL of SHAM
animals. Overall, the inhibition of PL and IL with LIDO
signiﬁcantly decreased PWL of SHAM animals (main
eﬀect of LIDO in PL: F1,103 = 11.63, P= 0.0009; main
eﬀect of LIDO in IL: F1,44 = 7.80; P= 0.0077), showing
Fig. 3. Radiant heat-evoked paw withdrawal latencies (PWL) of healthy control animals after intracerebral drug administrations in the prelimbic (PL;
A, B) or infralimbic (IL; C, D) cortex (GLU, glutamate, 50 nmol; LIDO, lidocaine, 2%; VEH, vehicle). (A) GLU in the PL increased the PWL 1 min after
its administration; (B) LIDO in the PL decreased the PWL 10 and 20 min after its administration; (C) GLU in the IL decreased the PWL 10–30 min
after its administration; (D) LIDO in the IL decreased the PWL 30 min after its administration. Graphs show the mean + SEM (VEH: nPL = 10;
nIL = 6; GLU: nPL = 10; nIL = 6; LIDO: nPL = 10; nIL = 7). Drug injections were performed at time point 0.
*/+P< 0.05; **/++P< 0.01;
***P< 0.001 (t-test with a Bonferroni correction for multiple comparisons; */**/***represent the comparison of injection results with pre-injection
(5 min) value; +/++represent the comparison of time point values of SHAM vs. ARTH).
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healthy rats. Post-hoc tests showed that these LIDO-
induced alterations in PWL lasted for 10–30 min
(Fig. 3B, D).
The following experiments focused on the prolonged
pronociceptive action of GLU in the IL.Eﬀect of IL pharmacological manipulation upon
nociceptive behaviorThe IL modulates heat-evoked nociceptive behavior of
SHAM and ARTH animals. To assess if the long-lasting
pronociceptive eﬀect of GLU microinjection in the IL was
due to activation of metabotropic rather than ionotropic
receptors, we selectively activated mGluR1 and mGluR5
in the IL and assessed its impact upon nociceptive
behavior of SHAM and ARTH animals. Additionally, we
also determined the time window during which drugs
microinjected into the IL aﬀected nociceptive behavior by
testing noxious heat-evoked PWL in SHAM and ARTH
rats at various time points after cortical drug
administrations (Figs. 4–6). IL injection of the VEH failed
to alter PWL (main eﬀect of time after VEH treatment:
F5,66 = 0.142; Fig. 4A), independent of the experimental
group (interaction experimental group  time after vehicle
treatment: F5,66 = 0.05). GLU or LIDO in the IL
signiﬁcantly decreased PWL of SHAM and ARTH
animals (main eﬀect of time after GLU treatment:
F5,59 = 14.80, P< 0.0001; main eﬀect of time after LIDOtreatment: F5,61 = 8.70, P< 0.0001) for 10–30 min after
drug injection (Figs. 4B, C). The pronociceptive eﬀects of
GLU or LIDO in the IL did not vary between the SHAM
and ARTH groups (interaction experimental group  time
after GLU microinjection: F5,59 = 0.48; interaction
experimental group  time after LIDO microinjection:
F5,61 = 0.70).
DHPG (an mGluR1/5 agonist) in IL signiﬁcantly
decreased PWL (main eﬀect of time after DHPG
treatment: F5,66 = 5.02, P= 0.006; Fig. 4D), an eﬀect
that varied with the experimental group (interaction
experimental group  time after cortical drug treatment:
F5,66 = 3.76, P= 0.0047). Post hoc tests indicated that
the pronociceptive eﬀect of DHPG in IL was signiﬁcantly
stronger in SHAM than ARTH animals 30 min after drug
treatment (Fig. 4C).
Prolonged pronociceptive behavior elicited by GLU in
the IL is not mediated by mGluR1 activation. To assess if
the mGluR1 was responsible for the long-lasting
pronociceptive eﬀect of GLU microinjection in the IL, we
selectively activated and/or inhibited mGluR1 in the IL
and assessed its impact on nociceptive behavior in
SHAM and ARTH animals.
The IL co-administration of DHPGwith MPEP (with the
purpose of activating mGluR1) had a signiﬁcant eﬀect on
PWL (main eﬀect of time after DHPG+MPEP
treatment: F5,74 = 4.07, P= 0.0026), that varied with the
experimental group (interaction experimental group 
time after drug treatment: F5,75 = 7.96, P< 0.0001).
Post hoc tests indicated that the combination of DHPG
Fig. 4. Radiant heat-evoked paw withdrawal latencies (PWL) after intracerebral administration in the infralimbic cortex (IL). Eﬀects of IL
administration of vehicle (VEH; A), glutamate (GLU, 50 nmol; B), LIDO (2%; C) and DHPG (an mGluR1/5 agonist, 50 nmol; D) in control (SHAM,
black full lines) and monoarthritic (ARTH, gray dashed lines) animals. Drug injections were performed at time point 0. Data are presented as mean
+ SEM. VEH: nSHAM = 6, nARTH = 8; GLU: nSHAM = 6, nARTH = 6; LIDO: nSHAM = 7, nARTH = 6; DHPG: nSHAM = 7, nARTH = 6.
*/+P< 0.05;
**P< 0.01; ***P< 0.001 (t-test with a Bonferroni correction for multiple comparisons; */**/***represent the comparison of injection results with pre-
injection (5 min) value; +represents the comparison of time point values of SHAM vs. ARTH).
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this antinociceptive eﬀect was signiﬁcantly stronger in the
SHAM than the ARTH group from 10 to 30 min after the
drug treatment (Fig. 5B). LY367385 alone (an mGluR1
antagonist) did not alter PWL (main eﬀect of time after
LY367385 treatment: F5,60 = 0.4909, P= 0.7818;
Fig. 5C), independent of the experimental group
(interaction experimental group  time after drug
treatment: F5,60 = 0.16). Co-administration of DHPG,
MPEP and LY367385 in the IL failed to alter PWL (main
eﬀect of time after DHPG+MPEP+ LY367358
treatment: F5,60 = 0.26, P= 0.9321), independent of the
experimental group (interaction experimental group 
time after drug treatment: F5,60 = 0.70; Fig. 5D).
IL co-administration of LY367385 and GLU
signiﬁcantly decreased PWL of SHAM and ARTH
animals (main eﬀect of time after LY367358 + GLU
treatment: F5,128 = 25.60, P< 0.0001) for 20–30 min
after drug injection (Fig. 5E). The pronociceptive eﬀects
of the combination of LY367385 and GLU in the IL did
not vary between SHAM and ARTH groups (interaction
experimental group  time after microinjection:
F5,128 = 0.94).
No changes were observed in PWL after vehicle
microinjection to the IL (main eﬀect of time after VEHtreatment: F5,66 = 0.14), independent of the
experimental group (interaction experimental
group  time after drug treatment: F5,66 = 0.05; Fig. 5A).
mGluR5 mediates the prolonged pronociceptive
behavior elicited by GLU in the IL. To assess if the
long-lasting pronociceptive eﬀect of GLU microinjection
was mediated through mGluR5 in the IL, we selectively
activated and/or inhibited mGluR5 in the IL and
assessed its impact on nociceptive behavior in SHAM
and ARTH animals.
CHPG (an mGluR5 agonist) in the IL signiﬁcantly
decreased PWL of SHAM and ARTH animals (main
eﬀect of time after CHPG treatment: F5,120 = 16,38,
P< 0.0001) for 10–40 min after drug injection (Fig. 6B).
The pronociceptive eﬀects of CHPG in the IL did not vary
between the SHAM and ARTH groups (interaction
experimental group  time after microinjection:
F5,120 = 0.30). IL administration of MPEP or MTEP alone
(mGluR5 antagonists) had a signiﬁcant eﬀect on PWL
(main eﬀect of time after MPEP treatment: F5,82 = 4.56;
P< 0.0001; main eﬀect of time after MTEP treatment:
F5,77 = 5.02; P= 0.0005). The eﬀect of MPEP or MTEP
alone in IL varied with the experimental group (interaction
experimental group  time after MPEP administration:
F5,82 = 4.56, P< 0.0001; interaction experimental
Fig. 5. Radiant heat-evoked paw withdrawal latencies (PWL) after intracerebral mGluR1 agonists/antagonists administration in the infralimbic
cortex (IL). Eﬀects of IL administration of vehicle (VEH; A), a combination of DHPG and MPEP (an mGluR1/5 agonist and an mGluR5 antagonist,
respectively; 50 nmol each; B), LY367385 (an mGluR1 antagonist, 40 nmol; C), a combination of DHPG, MPEP and LY367385 (50 nmol DHPG and
MPEP, 40 nmol LY367385; D) and a combination of LY367385 and GLU (40 nmol LY367385, 50 nmol GLU; E) in control (SHAM, black full lines)
and monoarthritic (ARTH, gray dashed lines) animals. Drug injections were performed at time point 0. Data are presented as mean + SEM. VEH:
nSHAM = 6, nARTH = 8; DHPG+MPEP: nSHAM = 9, nARTH = 6; LY367385: nSHAM = 6, nARTH = 6; DHPG+MPEP+ LY367385: nSHAM = 6,
nARTH = 6; LY367385 + GLU: nSHAM = 11, nARTH = 11.
*P< 0.05; **P< 0.01; ***/+++P< 0.001 (t-test with a Bonferroni correction for multiple
comparisons; */**/***represent the comparison of injection results with pre-injection (5 min) value; +++represent the comparison of time point
values of SHAM vs. ARTH).
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P= 0.0010). Post hoc tests indicated that PWL was
prolonged after MPEP or MTEP in the ARTH but not in
the SHAM group and that the PWL was signiﬁcantly
longer in the ARTH than the SHAM group 30–40 min
after MPEP or MTEP administration (Figs. 6C, D).Co-administration of MPEP/MTEP and GLU in
the IL failed to alter PWL (main eﬀect of time after
MPEP+ GLU treatment: F5,95 = 0.21; P= 0.9568;
main eﬀect of time after MTEP + GLU treatment: F5,66 =
0.25; P= 0.9396), independent of the experimental
group (interaction experimental group  time after
Fig. 6. Radiant heat-evoked paw withdrawal latencies (PWL) after intracerebral mGluR5 agonists/antagonists administration in the infralimbic
cortex (IL). Eﬀects of IL administration of vehicle (VEH; A), CHPG (an mGluR5 agonist, 50 nmol; B), MPEP (an mGluR5 antagonist, 50 nmol; C),
MTEP (an mGluR5 receptor antagonist, 50 nmol; D), MPEP+ GLU (50 nmol each; E) and MTEP +GLU (50 nmol each; F) in control (SHAM, black
full lines) and monoarthritic (ARTH, gray dashed lines) animals. Drug injections were performed at time point 0. Data are presented as mean
+ SEM. VEH: nSHAM = 6, nARTH = 8; CHPG: nSHAM = 11, nARTH = 11; MPEP: nSHAM = 7, nARTH = 9; MTEP: nSHAM = 6, nARTH = 9; MPEP
+GLU: nSHAM = 11, nARTH = 7; MTEP +GLU: nSHAM = 6, nARTH = 7.
*/+P< 0.05; **/++P< 0.01; ***/+++P< 0.001 (t-test with a Bonferroni
correction for multiple comparisons; */**/***represent the comparison of injection results with pre-injection (5 min) value; +/++/+++represent the
comparison of time point values of SHAM vs. ARTH).
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mental group  time after MTEP+ GLU treatment:
F5,66 = 0.26; Figs. 6E, F).
No changes were observed in PWL after vehicle
microinjection to the IL (main eﬀect of time after
VEH treatment: F5,66 = 0.14), independent of the
experimental group (interaction experimental group 
time after drug treatment: F5,66 = 0.05; Fig. 6A).ARTH animals present mechanical hyperalgesia in the
aﬀected knee joint. Four weeks after ARTH induction,
mechanically evoked LWT of the knee joint of ARTH
animals was signiﬁcantly decreased when compared to
SHAM (main eﬀect of experimental group: F1,26 = 6.50;
P= 0.0171), an eﬀect dependent of the tested limb
(interaction: experimental group  limb: F1,26 = 12.53;
P= 0.0015). Post hoc tests indicate that LWT in the
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when compared to the contralateral knee joint of the
ARTH group and to the ipsilateral knee joint of SHAM
group (Fig. 7A).
Motor performance was not altered after drug microin-
jection in the IL. Locomotor performance was assessed
in the Rotarod test to evaluate potential motor eﬀects
elicited by drug administration. The results obtained
show that although ARTH animals have a signiﬁcantly
decreased latency to fall when compared to the SHAM
group (main eﬀect of experimental group: F1,64 = 6.39,
P= 0.0140), none of the microinjected drugs had an
eﬀect on motor performance of SHAM and ARTH rats at
the time points tested in the nociceptive assessment
(main eﬀect of drug treatment: F7,64 = 0.10, P=
0.9980). This eﬀect was independent of the
experimental group (interaction experimental
group  drug treatment: F7,64 = 0.12; Fig. 7B).
DISCUSSION
In the present work, we demonstrate for the ﬁrst time that
administration of GLU to the IL induces prolonged
behavioral hyperalgesia. This eﬀect is mediated by the
mGluR5, since IL administration of a selective mGluR5
agonist mimicked the behavioral pronociceptive eﬀect
evoked by GLU in both SHAM and ARTH animals.
Moreover, previous administration of an antagonist of
mGluR5, but not mGluR1, in the IL was eﬀective in
blocking the pronociceptive eﬀect of GLU in both
experimental groups. The increase in withdrawal latency
(antinociception) observed after blocking IL mGluR5 in
ARTH animals only, suggests an increased tonic
activation of these receptors in chronic inﬂammation of
the joint.
The eﬀect induced by activation of mGluR1 in the IL
was studied indirectly by IL co-administration of an
mGluR1/5 agonist and an mGluR5 antagonist. The
antinociceptive eﬀect induced by this combination of
drugs in ARTH but not in SHAM animals suggests that
following the development of monoarthritis, the net
eﬀect of the descending pathways recruited by mGluR1
is antinociceptive. It might be argued that the
antinociception induced by IL co-administration of the
mGluR1/5 agonist and mGluR5 antagonist in the ARTH
group was due to blocking of the mGluR5-driven
pronociceptive drive rather than activation of the
mGluR1; however, previous administration of an
mGluR1 antagonist blocked this antinociceptive eﬀect,
indicating an activation of mGluR1 instead of the
inactivation of mGluR5. Additionally, the ﬁndings that IL
administration of an mGluR5 agonist alone had a
pronociceptive action whereas the mGluR1/5 agonist
alone failed to alter nociception, support the proposal
that mGluR1 in the IL of ARTH animals has indeed an
antinociceptive eﬀect.
Technical considerations
In this work, we have chosen to evaluate heat-evoked
PWL, a test in which the baseline values of SHAM andARTH animals are similar (Fig. 4A), instead of
mechanical LWT, where ARTH animals have
signiﬁcantly decreased values when compared to SHAM
(Fig. 7A). Our choice was based on the technical
diﬀerences between the PAM and the Hargreaves tests.
The PAM test requires not only that the animals are
heavily handled by the researcher during each
experimental session, but also that the knee joint is
noxiously stimulated twice at each time point before and
after drug administration. Thus, one test would imply the
aﬀected joint to undergo 12 noxious stimulations in a
short period of time (60 min) which by itself might bias
the evaluation, as the mechanical hyperalgesia in K/C
model is use-dependent. By contrast, in the Hargreaves
test animals are placed in a compartment for the
duration of the experimental session (no handling is
involved) and the thermal stimulus is applied from
underneath the plantar surface of the hindpaw, thus
sparing the joint, but still activating ascending and
descending pain modulatory pathways. Therefore, we
are not showing a reversion of mechanical hyperalgesia
when treating ARTH animals, but that the IL promotes
descending facilitation both in health and in disease,
and that this eﬀect is mediated by mGluR, mainly
mGluR5.
The opposing roles of the PL and IL in descending
modulation of nociception are associated to the
activation of diﬀerent types of GLU receptors
The dorsal portion of the mPFC, that includes the ACC, is
among the most studied cortical areas in pain processing
(Apkarian et al., 2005; Tracey and Mantyh, 2007), but
only a few studies have been centered in the PL and IL
cortices in the rodent brain. So far, these areas have been
mostly implicated in the attentional and cognitive process-
ing of pain (Apkarian et al., 2005), but there is some evi-
dence that they actively modulate nociception. In fact,
reports show that sustained pain conditions lead to a
decrease of basal neuronal activity in the mPFC (Ji and
Neugebauer, 2011; Luongo et al., 2013). The behavioral
data of the present study shows that the PL and the IL
modulate nociception and that the blockade of these
regions with LIDO decreased PWL, suggesting a tonic
antinociceptive role in pain control.
Since the PL and the IL are adjacent to one another, it
could be argued that there is widespread diﬀusion of
drugs, resulting in a simultaneous activation/inactivation
of these areas due to drug spillage outside of the
targeted area of administration. However, GLU
administration to the PL and IL had opposite eﬀects on
heat-evoked PWL, increasing and decreasing
withdrawal latencies, respectively. Interestingly, GLU in
the PL increased withdrawal latencies within 30–60 s, a
short onset of action typical of the activation of
ionotropic GLU receptors. Indeed, Millecamps et al.
(2007) reported that activation of NMDA receptors in PL
induced analgesia. By contrast, GLU in the IL decreased
PWL, but only 10–30 min after drug administration, a
response typically associated with the activation of
mGluRs. This hypothesis is supported ﬁrstly, by the
decrease in PWL observed after the IL microinjection of
Fig. 7. (A) Evaluation of limb withdrawal threshold (LWT) in the pressure application measurement (PAM) 4 weeks after arthritis induction. The
LWT of ARTH (n= 7) animals was signiﬁcantly decreased when compared to results of control SHAM (n= 8) animals (mechanical hyperalgesia).
(B) Drug eﬀects on locomotion. Evaluation of performance in the rotarod test after drug injection in the infralimbic cortex (IL) of SHAM and ARTH
rats showed that none of the drugs had an eﬀect on the latency to fall 10–30 min after administration in the IL. Data are presented as mean + SEM.
**P< 0.01; ***P< 0.001.
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eﬀect of GLU in the IL; and secondly, by the lack of
changes in nociceptive behavior when GLU microinjection
was preceded by administration of MPEP or MTEP, two
diﬀerent mGluR5 antagonists.
Interestingly, GLU and CHPG microinjection
decreased PWL similar to what observed after LIDO
microinjection. A potential explanation for this ﬁnding is
that the eﬀect of mGluR5 activation triggers an inhibitory
mechanism, leading to suppression of neuronal
discharge in the IL. In line with this hypothesis, a recent
study by Pollard et al. (2014) has shown that mGluR5
activation leads to inhibition of neuronal activity in the ven-
tral mPFC by promoting feed-forward inhibition. However,
there are also contrasting reports that show mGluR5 acti-
vation in the ventral mPFC increases neuronal excitability
by reducing the release of presynaptic GABA (Kiritoshi
et al., 2013; Ji and Neugebauer, 2014). As a modulator
of neuronal excitability (Schoepp, 2001), mGluR5 activa-
tion/inactivation can aﬀect several mechanisms, thus, fur-
ther studies are still needed to fully understand the
pathways underlying descending modulation of nocicep-
tion modulated by mGluR5 in the IL.mGluRs mediate GLU-driven descending facilitation
from the IL
In the present work, IL administration of the selective
mGluR5 agonist CHPG as well as of exogenous GLU
induced delayed and long-lasting pronociceptive eﬀects
that were identical in both SHAM and ARTH animals.
Although the mechanism driving this eﬀect is not fully
understood, a study by Ji and Neugebauer (2014) showed
the administration of an mGluR5-positive allosteric modu-
lator (which increases receptor availability without activat-
ing it) increases background and evoked activity of IL
pyramidal cells in healthy animals. However, in animals
with sustained inﬂammatory pain, this facilitatory eﬀect
was only observed following co-application of a CB1
receptor agonist with the mGluR5 allosteric modulator
(Ji and Neugebauer, 2014). This ﬁnding indicates thatsustained inﬂammatory pain promotes remodeling of sig-
naling pathways involving the IL and mGluRs. In line with
this evidence, we observed that MPEP or MTEP, both
mGluR5 antagonists, in the IL produced antinociception
only in ARTH animals, further suggesting that mGluR5
in the IL plays a role in tonic facilitation of nociception in
chronic inﬂammatory disorders. Other studies using ani-
mal models of inﬂammatory pain have reported antinoci-
ception (Hudson et al., 2002; Zhu et al., 2004) and
inhibition of spontaneous burst activity in the mPFC
(Houmayoun and Moghaddam, 2006) after systemic
administration of an mGluR5 antagonist. Together, the
eﬀects observed after blocking mGluR5 suggest this
receptor plays an important role in the modulation of noci-
ceptive transmission in chronic inﬂammatory pain states.
Although we cannot directly compare the eﬀect of system-
ically administrated drugs to the eﬀect of local microinjec-
tions in a speciﬁc brain area, the present and earlier
results (Ji and Neugebauer, 2014) are in line with the pro-
posal that the mGluR5-mediated mechanisms in the IL
contribute to the descending control of nociception and
its modulation in inﬂammatory conditions.
Activation of mGluR1 with a combination of DHPG
and MPEP in the IL of SHAM animals had no eﬀect
upon nociceptive behavior, while it increased heat-
evoked PWL (antinociception) in the ARTH group.
These results suggest that in experimental monoarthritis
a descending antinociceptive pathway can be activated
if mGluR1 in the IL are recruited. Yet, inactivation of
mGluR1 in the IL with antagonist LY367385 had no
eﬀect on PWL of SHAM or ARTH animals, indicating
that mGluR1 are not tonically activated in the IL.
Interestingly, an earlier electrophysiological study
showed PL mGluR1 are important players in the
decrease of the spontaneous activity of PL neurons
caused by pain-induced hyperactivity of the amygdala in
sustained inﬂammatory conditions (Ji and Neugebauer,
2014). Overall, although we were able to evoke an
antinociceptive eﬀect after the activation of mGluR1 in
the IL, the impact of this pathway toward nociception
remains unclear, since the blockade of mGluR1 had no
118 A. David-Pereira et al. / Neuroscience 312 (2016) 108–119eﬀect upon nociceptive behavior and the pronociceptive
eﬀect of mGluR5 prevailed in controls and animals with
experimental monoarthritis.CONCLUSIONS
Drugs acting at mGluRs have more subtle eﬀects on
glutamatergic transmission than agonists and
antagonists of ionotropic GLU receptors, as well as
fewer side eﬀects on normal functions (Conn and Pin,
1997; Schoepp, 2001; Neugebauer, 2002). Hence, the
modulation of mGluRs allows a ﬁne-tuning of cellular
responses to glutamatergic inputs. The results of this
study provide strong evidence the IL is involved in the
descending modulation of nociception and mGluRs, par-
ticularly mGluR5, might contribute to inﬂammatory
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